Multidrug-resistant tuberculosis (MDR-TB) and extensively drug-resistant tuberculosis (XDR-
TB) continue to challenge physicians and public health specialists. Global treatment …

MDR-TB is a lethal form of TB caused by Mycobacterium tuberculosis strains, which are
resistant to rifampicin and isoniazid. It should be suspected in patients living in high MDRTB …

Patients with multidrug-resistant (MDR) tuberculosis (TB), in particular those with pre-
extensively drug-resistant (pre-XDR) and extensively drug-resistant (XDR)-TB, and those …

Loss to follow-up (LFU) of≥ 2 consecutive months contributes to the poor levels of treatment
success in multidrug-resistant tuberculosis (MDR-TB) reported by TB programmes. We …

Tuberculosis (TB) presents new challenges as a global public health problem, especially at
a time of increasing threats to some particular patients due to Human Immunodeficiency …

SETTING: Tajikistan is among the 30 countries with the highest multidrug-resistant
tuberculosis (MDR-TB) burden. OBJECTIVE: To investigate the risk factors for unfavourable …

Extensively drug-resistant tuberculosis (XDR TB) has extremely poor treatment outcomes in
adults. Limited data are available for children. We report on clinical manifestations …

Setting: Phase II trials for bedaquiline (BDQ) and delamanid (DLM) were completed by 2011
and the drugs were approved by stringent regulatory authorities for the treatment of …

Globally in 2016, 19% of previously treated tuberculosis (TB) cases and 4.1% of newly
diagnosed cases were reported to be resistant to isoniazid and rifampicin (multidrug …

RESUMO A tuberculose multirresistente e a tuberculose extensivamente resistente ainda
são um desafio para médicos e especialistas em saúde pública. Os desfechos globais do …